Skip to main content
Premium Trial:

Request an Annual Quote

23andMe Raises $250M in Funding Round

NEW YORK (GenomeWeb) – 23andMe has raised $250 million in funding, the consumer genomics firm announced today.

23andMe said it plans to use the money to grow its customer base, expand its therapeutics group, and invest in its genetic research platform. With this latest funding, 23andMe has raised $491 million from a range of investors, including technology and health science companies, angel investors, and venture capital firms.

This funding round was led by Sequoia Capital and included Euclidean Capital, Altimeter Capital, and the Wallenberg Foundation, all new investors in 23andMe. Current investors Fidelity Management & Research Company and Casdin Capital also contributed funding.

Roelof Botha, partner at Sequoia Capital, will join 23andMe's board of directors. The firm also noted that Neal Mohan, chief product officer at YouTube and a senior VP at Google, joined the board in July. 

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.